Imunon (IMNN) Competitors $0.91 +0.02 (+1.68%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends IMNN vs. PDSB, SPRO, OPTN, DYAI, XLO, TNXP, IVVD, ACHL, ICCC, and ALVRShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include PDS Biotechnology (PDSB), Spero Therapeutics (SPRO), OptiNose (OPTN), Dyadic International (DYAI), Xilio Therapeutics (XLO), Tonix Pharmaceuticals (TNXP), Invivyd (IVVD), Achilles Therapeutics (ACHL), ImmuCell (ICCC), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. Imunon vs. PDS Biotechnology Spero Therapeutics OptiNose Dyadic International Xilio Therapeutics Tonix Pharmaceuticals Invivyd Achilles Therapeutics ImmuCell AlloVir Imunon (NASDAQ:IMNN) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Does the MarketBeat Community favor IMNN or PDSB? PDS Biotechnology received 53 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 69.61% of users gave PDS Biotechnology an outperform vote. CompanyUnderperformOutperformImunonOutperform Votes18100.00% Underperform VotesNo VotesPDS BiotechnologyOutperform Votes7169.61% Underperform Votes3130.39% Do analysts rate IMNN or PDSB? Imunon currently has a consensus target price of $20.50, indicating a potential upside of 2,145.10%. PDS Biotechnology has a consensus target price of $11.67, indicating a potential upside of 704.60%. Given Imunon's stronger consensus rating and higher probable upside, research analysts plainly believe Imunon is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is IMNN or PDSB more profitable? PDS Biotechnology's return on equity of -139.57% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -230.05% -128.98% PDS Biotechnology N/A -139.57%-67.22% Do insiders & institutionals believe in IMNN or PDSB? 4.5% of Imunon shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 9.5% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer IMNN or PDSB? In the previous week, Imunon and Imunon both had 1 articles in the media. PDS Biotechnology's average media sentiment score of 1.26 beat Imunon's score of -1.00 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Imunon Negative PDS Biotechnology Positive Which has higher earnings and valuation, IMNN or PDSB? Imunon has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K26.48-$19.51M-$1.89-0.48PDS BiotechnologyN/AN/A-$42.94M-$1.16-1.25 Which has more volatility and risk, IMNN or PDSB? Imunon has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. SummaryPDS Biotechnology beats Imunon on 8 of the 15 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.05M$6.37B$5.23B$8.96BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-0.489.4187.2917.29Price / Sales26.48310.261,255.8979.02Price / CashN/A61.4443.8235.97Price / Book0.646.055.324.79Net Income-$19.51M$154.90M$122.78M$225.07M7 Day Performance1.47%-1.72%-0.19%1.51%1 Month Performance9.95%2.69%3.72%4.68%1 Year Performance54.74%2.78%27.31%20.92% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.1479 of 5 stars$0.91+1.7%$20.50+2,145.1%+42.2%$13.05M$500,000.00-0.4830Short Interest ↑Negative NewsPDSBPDS Biotechnology1.6019 of 5 stars$1.42+0.7%$11.67+721.6%-64.5%$53.12MN/A-1.2220News CoveragePositive NewsGap DownSPROSpero Therapeutics4.6348 of 5 stars$0.95-3.2%$5.00+426.9%-36.8%$51.74M$89.87M13.56150OPTNOptiNose4.3866 of 5 stars$5.02-5.3%$26.00+417.9%-67.3%$50.50M$75.67M-17.93190Analyst ForecastNews CoverageGap UpDYAIDyadic International3.126 of 5 stars$1.65flat$6.00+263.6%+2.0%$48.82M$3.36M-7.177Short Interest ↓Positive NewsGap UpXLOXilio Therapeutics3.1522 of 5 stars$1.10flat$4.00+263.6%+67.0%$48.35M$4.62M-0.6470Short Interest ↑Positive NewsTNXPTonix Pharmaceuticals3.0618 of 5 stars$0.26-8.0%$53.50+20,765.8%-97.4%$47.92M$11.29M0.0050Analyst ForecastShort Interest ↑Gap DownIVVDInvivyd3.0659 of 5 stars$0.40-11.7%$7.89+1,875.8%-90.1%$47.75M$11.56M-0.20100Short Interest ↑ACHLAchilles Therapeutics2.6591 of 5 stars$1.16-2.1%$4.00+244.8%+31.9%$47.68MN/A-0.70250Short Interest ↑News CoveragePositive NewsICCCImmuCell0.1079 of 5 stars$5.33+2.7%N/A-3.8%$47.50M$23.84M-10.6670Short Interest ↑News CoverageALVRAlloVir1.7985 of 5 stars$0.41-6.6%N/A-40.2%$47.38MN/A-0.47110Stock SplitShort Interest ↓News CoverageHigh Trading Volume Related Companies and Tools Related Companies PDSB Competitors SPRO Competitors OPTN Competitors DYAI Competitors XLO Competitors TNXP Competitors IVVD Competitors ACHL Competitors ICCC Competitors ALVR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMNN) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts